» Articles » PMID: 17555433

The Mycobacterium Tuberculosis FAS-II Condensing Enzymes: Their Role in Mycolic Acid Biosynthesis, Acid-fastness, Pathogenesis and in Future Drug Development

Overview
Journal Mol Microbiol
Date 2007 Jun 9
PMID 17555433
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Mycolic acids are very long-chain fatty acids representing essential components of the mycobacterial cell wall. Considering their importance, characterization of key enzymes participating in mycolic acid biosynthesis not only allows an understanding of their role in the physiology of mycobacteria, but also might lead to the identification of new drug targets. Mycolates are synthesized by at least two discrete elongation systems, the type I and type II fatty acid synthases (FAS-I and FAS-II respectively). Among the FAS-II components, the condensing enzymes that catalyse the formation of carbon-carbon bonds have received considerable interest. Four condensases participate in initiation (mtFabH), elongation (KasA and KasB) and termination (Pks13) steps, leading to full-length mycolates. We present the recent biochemical and structural data for these important enzymes. Special emphasis is given to their role in growth, intracellular survival, biofilm formation, as well as in the physiopathology of tuberculosis. Recent studies demonstrated that phosphorylation of these enzymes by mycobacterial kinases affects their activities. We propose here a model in which kinases that sense environmental changes can phosphorylate the condensing enzymes, thus representing a novel mechanism of regulating mycolic acid biosynthesis. Finally, we discuss the attractiveness of these enzymes as valid targets for future antituberculosis drug development.

Citing Articles

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis.

Diab A, Dickerson H, Al Musaimi O Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861133 PMC: 11768153. DOI: 10.3390/ph18010070.


A machine learning-based strategy to elucidate the identification of antibiotic resistance in bacteria.

Parthasarathi K, Gaikwad K, Rajesh S, Rana S, Pandey A, Singh H Front Antibiot. 2025; 3():1405296.

PMID: 39816256 PMC: 11732175. DOI: 10.3389/frabi.2024.1405296.


Domain architecture of the MabR (), a member of the PucR transcription factor family.

Megalizzi V, Tanina A, Grosse C, Mirgaux M, Legrand P, Dias Mirandela G Heliyon. 2024; 10(22):e40494.

PMID: 39641026 PMC: 11617747. DOI: 10.1016/j.heliyon.2024.e40494.


Studying the dynamics of the drug processing of pyrazinamide in Mycobacterium tuberculosis.

Requena D, Supo-Escalante R, Sheen P, Zimic M PLoS One. 2024; 19(8):e0309352.

PMID: 39208342 PMC: 11361689. DOI: 10.1371/journal.pone.0309352.


Tailoring selective triclosan azo-adducts: Design, synthesis, and anti-mycobacterial evaluation.

Shekhar , Alcaraz M, Seboletswe P, Manhas N, Kremer L, Singh P Heliyon. 2023; 9(11):e22182.

PMID: 38034623 PMC: 10685269. DOI: 10.1016/j.heliyon.2023.e22182.